Tofacitinib for the treatment of alopecia areata and variants in adolescents.
4/5 보강
TL;DR
The use of tofacitinib and other Janus kinase inhibitors for the treatment of AA in this age group should be further evaluated in prospective clinical trials.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: AA treated with tofacitinib
I · Intervention 중재 / 시술
tofacitinib
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Tofacitinib is a promising therapy for AA in adolescents. The use of tofacitinib and other Janus kinase inhibitors for the treatment of AA in this age group should be further evaluated in prospective clinical trials.
📑 코퍼스 인용 관계
· 인용됨 41
📑 인용한 논문 (6) ▾
- Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universali… Cureus · 2025
- Exploring the Use of Topical Tofacitinib in Pediatric Alopecia Totalis. International journal of trichology · 2025
- Janus kinase inhibitors for alopecia areata: a review of clinical data. Frontiers in immunology · 2025
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Popul… Dermatology practical & conceptual · 2024
- Treatment Options for Alopecia Areata in Children and Adolescents. Paediatric drugs · 2024
- Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopeci… Archives of dermatological research · 2024
연도별 인용 (2017–2025) · 합계 173
OpenAlex 토픽 ·
Hair Growth and Disorders
Skin and Cellular Biology Research
Facial Rejuvenation and Surgery Techniques
Abstract 🌐 Abstract
[BACKGROUND] There are no reliably effective therapies for alopecia areata (AA).
[OBJECTIVE] We sought to evaluate the benefit and adverse effects of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of adolescent patients with AA.
[METHODS] We reviewed the records of 13 adolescent patients with AA treated with tofacitinib. Severity of disease was assessed using the Severity of Alopecia Tool (SALT). Adverse events were evaluated by laboratory monitoring, physical examinations, and review of systems.
[RESULTS] Thirteen patients, aged 12 to 17 years, with AA were treated with tofacitinib. Nine patients experienced clinically significant hair regrowth. Median percent change in SALT score was 93% (mean 61%; 1%-100%) at an average of 6.5 months of treatment. Adverse events were mild.
[LIMITATIONS] Limitations include the retrospective nature of the data, small sample size, and lack of a control group.
[CONCLUSION] Tofacitinib is a promising therapy for AA in adolescents. The use of tofacitinib and other Janus kinase inhibitors for the treatment of AA in this age group should be further evaluated in prospective clinical trials.
[OBJECTIVE] We sought to evaluate the benefit and adverse effects of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of adolescent patients with AA.
[METHODS] We reviewed the records of 13 adolescent patients with AA treated with tofacitinib. Severity of disease was assessed using the Severity of Alopecia Tool (SALT). Adverse events were evaluated by laboratory monitoring, physical examinations, and review of systems.
[RESULTS] Thirteen patients, aged 12 to 17 years, with AA were treated with tofacitinib. Nine patients experienced clinically significant hair regrowth. Median percent change in SALT score was 93% (mean 61%; 1%-100%) at an average of 6.5 months of treatment. Adverse events were mild.
[LIMITATIONS] Limitations include the retrospective nature of the data, small sample size, and lack of a control group.
[CONCLUSION] Tofacitinib is a promising therapy for AA in adolescents. The use of tofacitinib and other Janus kinase inhibitors for the treatment of AA in this age group should be further evaluated in prospective clinical trials.
The use of tofacitinib and other Janus kinase inhibitors for the treatment of AA in this age group should be further evaluated in prospective clinical trials.
APA 7
Craiglow, B. G., Liu, L. Y., & King, B. A. (2017). Tofacitinib for the treatment of alopecia areata and variants in adolescents.. Journal of the American Academy of Dermatology, 76(1), 29-32. https://doi.org/10.1016/j.jaad.2016.09.006
Vancouver
Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. Jour. Amer. Acad. Derm.. 2017;76(1):29-32. doi:10.1016/j.jaad.2016.09.006
AMA 11
Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. Jour. Amer. Acad. Derm.. 2017;76(1):29-32. doi:10.1016/j.jaad.2016.09.006
Chicago
Craiglow, B. G., Liu, L. Y., and King, B. A.. 2017. "Tofacitinib for the treatment of alopecia areata and variants in adolescents." Journal of the American Academy of Dermatology 76 (1): 29-32. https://doi.org/10.1016/j.jaad.2016.09.006
MLA 9
Craiglow, B. G., et al. "Tofacitinib for the treatment of alopecia areata and variants in adolescents." Journal of the American Academy of Dermatology, vol. 76, no. 1, 2017, pp. 29-32. doi:10.1016/j.jaad.2016.09.006.
PMID
27816292 ↗
추출된 의학 개체 (NER)
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 | |
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 | |
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 5/8 (63%)
· 참조 0편 · 후속 5편
이 논문을 인용한 후속 연구 20
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.
- Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.
- The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meanin…
- Treatment of pediatric alopecia areata: A systematic review.
- JAK inhibitors in dermatology: The promise of a new drug class.
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.
- Alopecia Areata: An Updated Review for 2023.
- JAK Inhibitors for Treatment of Alopecia Areata.
- Baricitinib for the Treatment of Alopecia Areata.
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
- The current state of knowledge of the immune ecosystem in alopecia areata.
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
- Development of the Scalp Hair Assessment PRO™ measure for alopecia areata.
- New and Emerging Therapies for Alopecia Areata.
- Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Revie…
- Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clin…
- Alopecia Areata: An Update on Treatment Options for Children.
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
- A Practical Approach to the Diagnosis and Management of Hair Loss in Children and Adolescents.
같은 제1저자의 인용 많은 논문 (4)
- Tofacitinib for the treatment of alopecia areata in preadolescent children.
- Topical Ruxolitinib for the Treatment of Alopecia Universalis.
- Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes.
- The close resemblance between patients with severe alopecia areata and those with cancer: What hair tells us about wellness or grave illness.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Alopecia areata.
TL;DRAlopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the…
-
Epidemiology and burden of alopecia areata: a systematic review.
TL;DRAA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approxi…
-
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
TL;DRIn two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
TL;DRAlthough a variety of medical, surgical, light‐based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select ap…
-
Hair follicle immune privilege and its collapse in alopecia areata.
TL;DRA key goal for effective AA management is the re‐establishment of a functional HF IP, which will also provide superior protection from disease relapse, and may confer increased sus…